What does a PAPP‑A (pregnancy‑associated plasma protein‑A) level of 0.639 MoM indicate regarding my risk for chromosomal abnormalities and recommended next steps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

PAPP-A 0.639 MoM: Interpretation and Next Steps

Your PAPP-A level of 0.639 MoM is within the normal range and does not indicate increased risk for Down syndrome or other chromosomal abnormalities, but you should still complete your first-trimester combined screening with nuchal translucency (NT) measurement and free beta-hCG or total hCG for comprehensive risk assessment.

Understanding Your Result

Your PAPP-A value of 0.639 MoM falls above all clinically significant cut-offs for chromosomal abnormalities:

  • Down syndrome screening threshold: Values below 0.5 MoM are typically associated with increased risk 12
  • Other aneuploidies threshold: Values below 0.25 MoM warrant additional concern 3
  • Your result (0.639 MoM): Comfortably above both thresholds

Research demonstrates that Down syndrome pregnancies have a median PAPP-A of 0.30 MoM 1, while trisomy 18 shows 0.17 MoM and trisomy 13 shows 0.25 MoM 2. Your value is more than double these concerning levels.

Recommended Next Steps

Complete your first-trimester combined screening (11-13 weeks gestation) which should include 4:

  1. Nuchal translucency (NT) measurement - ultrasound measurement of fluid at back of fetal neck
  2. Free beta-hCG or total hCG - second blood marker
  3. Maternal age - incorporated into final risk calculation

The combined test using all three parameters (PAPP-A, NT, and hCG) achieves detection rates of 77-82% for Down syndrome with only 3-5% false positive rate 4. PAPP-A alone is insufficient for risk assessment - the markers work synergistically.

Alternative Screening Option

Consider cell-free DNA testing (NIPT) as a superior alternative 5:

  • Detection rate for trisomy 21: 98.83% (vs. 77-82% for combined screening)
  • False positive rate: 0.07% (vs. 3-5% for combined screening)
  • Positive predictive value: 91.8% for Down syndrome 5
  • NIPT demonstrates consistently higher performance than traditional biochemical screening for all common trisomies

Important Caveats About PAPP-A

While your PAPP-A is reassuring for chromosomal risk, be aware that low PAPP-A (below 0.4-0.5 MoM) is associated with pregnancy complications in chromosomally normal fetuses 67:

  • Preterm birth
  • Intrauterine growth restriction (IUGR)
  • Pre-eclampsia
  • Stillbirth

Your value of 0.639 MoM does not fall into this high-risk category, but values below 0.40 MoM warrant increased surveillance throughout pregnancy 7. The optimal timing for PAPP-A measurement is at 9 weeks gestation, with discriminatory power decreasing after this point 4.

Risk Cut-offs for Screen-Positive Results

Current guidelines define screen-positive results as 4:

  • First trimester risk: ≥1:200 (equivalent to 35-year-old maternal age risk)
  • Second trimester risk: ≥1:270
  • Some programs use 1:150 or 1:300 as alternative thresholds

Your final risk will be calculated combining all screening parameters, not PAPP-A alone.

What NOT to Do

Do not repeat PAPP-A testing - repeat sampling is discouraged except for suspected sample mix-up 4. If you obtain additional screening, it should be interpreted as supplementary information, not a replacement value.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.